Cloud Cybersecurity & Infrastructure Resilience · Data Provider / Broker
Veeva
Life sciences cloud software and data platform provider.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Veeva Systems Inc.
- Entity type
- COMPANY
- Founded
- 2007
- Headquarters
- United States
- Company size
- >5,000
- Market cluster / sector
- Cloud Cybersecurity & Infrastructure Resilience
- Market role
- Data Provider / Broker
- Ticker
- VEEV
- Official website
- veeva.com
What Veeva does
Veeva operates a vertical enterprise software model focused on regulated life sciences workflows. It creates value by offering a sector-specific cloud platform and adjacent applications that replace fragmented legacy systems, support compliance requirements, centralise content and operational data, and connect multiple functions across the product lifecycle. Revenue expands through module adoption, platform standardisation, multi-year enterprise contracts, and attached data products.
Category differentiation
Veeva is not a general consumer app or horizontal marketing platform. It is a sector-specific enterprise software and data provider focused on regulated life sciences workflows.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Veeva Systems Inc. is a public B2B software company that builds cloud applications and data products for the life sciences sector. Its product estate spans regulated content management, clinical operations, development, quality, safety, medical affairs, CRM, and commercial data, with a common platform architecture designed for pharmaceutical, biotech, and related regulated organisations. The company primarily generates revenue from recurring enterprise software subscriptions, with additional monetisation from data subscriptions, modular product licensing, and selective usage-based pricing for newer capabilities. Its customers are mainly large life sciences enterprises and their functional teams across R&D, regulatory, quality, medical, commercial, and clinical operations.
Company news briefing
Briefing updated:
Veeva continues to expand its enterprise footprint with global deployments of its Vault CRM platform by major life sciences clients such as Eli Lilly and Servier. Building on strong financial growth driven by core subscription revenues and the integration of Rise Healthcare Tech, the company has accelerated clinical workflows through innovations like the Study Builder Agent and expanded key industry partnerships with IQVIA.
Business model & monetisation
The company mainly uses recurring enterprise SaaS subscriptions priced by product suite, user counts, and deployment scope. It also monetises proprietary data products through subscription licensing, supports tiered product packaging across CRM and platform modules, and has introduced usage-based charging for some newer AI-driven capabilities. Commercial upside comes from cross-selling additional clouds, data assets, and acquired capabilities into existing enterprise accounts.
- Enterprise software subscriptions
- Recurring SaaS contracts across platform and application suites
- Data subscriptions
- Licensed access to commercial and clinical data products
- Tiered product licensing
- Module and licence-level packaging within CRM and other suites
- Usage-based AI capabilities
- Consumption-based pricing for newer AI-driven features
Products & capabilities
| Product | Description | Source |
|---|---|---|
| Veeva Vault Platform | Veeva Vault Platform is a cloud-based enterprise platform that provides the underlying infrastructure, data model, and application framework for all Veeva applications. It enables regulated content and data management across clinical, regulatory, quality, and commercial domains with built-in compliance, security, and integration capabilities. The platform supports extensibility and interoperability with external systems through APIs and data services. |
|
| Veeva Vault CRM | Veeva Vault CRM is a cloud-based customer relationship management platform tailored for life sciences organisations. It connects sales, marketing, and medical teams on a unified customer database, enabling compliant engagement with healthcare professionals and stakeholders. The system includes capabilities such as account management, content sharing, territory planning, and multichannel engagement workflows. |
|
POLARIS7 WORKSPACE
Go deeper on Veeva and its market context
Access extended corporate structures, historical M&A and partnership links, technical footprint data, and automated Watchlist briefings grounded in primary sources.
- Corporate & subsidiary hierarchy
- Competitor & partner network
- Automated Watchlist briefings
Competitors & alternatives
Track competitor shifts
Receive automated telemetry on strategic moves, acquisitions, and market share shifts across Veeva's competitive landscape.
Imaging data platform for regulated healthcare and life sciences research.
Capital markets infrastructure, financial data and enterprise fintech provider.
Enterprise content cloud for secure collaboration, workflows, and AI.
Healthcare-focused identity and access management software provider.
Enterprise consulting and vertical software provider for regulated industries.
Side-by-side comparisons
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
8-K Financial Filing Analysis for Veeva (2026-11-06)
financials · Recorded impact score: 3.2/5
On November 5, 2026, Veeva Systems Inc. furnished a Form 8-K under Item 2.02 detailing updates provided at its 2026 Investor Day presentation. Chief Financial Officer Brian Van Wagener confirmed that the company expects its third quarter fiscal year 2027 financial results to meet or exceed the preliminary guidance initially issued during its August 26, 2026 earnings conference call. The affirmation reflects operational stability and execution momentum across Veeva's life sciences cloud and data software portfolio as it progresses through the second half of fiscal 2027.
- During its Investor Day on November 5, 2026, Veeva reaffirmed that Q3 FY2027 financial performance is expected to meet or exceed prior guidance.
- The baseline guidance referenced was previously issued during the quarterly earnings conference call on August 26, 2026.
Veeva Summit to Showcase Agentic AI and Data Innovations
AI in Life Sciences Marketing · Recorded impact score: 2/5
Veeva Systems announced that leaders from AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, UCB, and other biopharma companies will present new strategies for commercial and medical excellence at the Veeva Commercial Summit, Europe, scheduled for November 18-19, 2026, in Copenhagen. The summit will showcase how industry-specific AI enables sales, marketing, and medical teams to improve customer engagement, derive insights, and accelerate compliant content delivery. Key topics include agentic customer engagement, agentic CRM, agentic MLR for content approvals, and building a data foundation for AI with HCP access data and trusted data platforms. The event will feature over 100 sessions and 1,200+ industry experts, highlighting innovations with Veeva's Commercial Cloud and Data Cloud.
- Veeva Commercial Summit Europe is scheduled for November 18-19, 2026, in Copenhagen.
- The summit will feature over 100 sessions and 1,200+ industry experts.
IQVIA Expands Veeva Partnership with Clinical Operations Applications
Partnership · Recorded impact score: 1/5
IQVIA and Veeva Systems announced an expansion of their partnership, with IQVIA selecting Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications for its clinical development studies. This extends the previously announced EDC partnership. The collaboration aims to increase trial speed and efficiency, strengthen site centricity, and improve decision-making for clinical research customers. All Veeva clinical solutions will also be available through IQVIA for sponsors seeking a full Veeva technology stack. Executives from both companies emphasized the benefits of integrated technologies and customer flexibility in choosing EDC, RTSM, and eCOA solutions. The announcement was made on October 13, 2026, ahead of the Veeva R&D and Quality Summit scheduled for October 20-21 in Boston.
- IQVIA selected Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications.
- Partnership expansion extends the previously announced EDC partnership.
Servier Adopts Veeva OpenData Globally for AI
AI & Data Infrastructure · Recorded impact score: 3/5
Servier, a French pharmaceutical company, is standardizing its customer reference data across more than 80 countries with Veeva OpenData, part of Veeva Data Cloud. This initiative builds on Servier's use of Veeva Link Key People and aims to create an AI-ready data foundation by harmonizing fragmented data silos. The centralized data will help commercial and medical teams gain faster insights and improve efficiency. Liam Hanrahan, Director of Global Operations Excellence at Servier, highlighted that the centralized data will improve processes and enable a semantic layer for better engagement with key healthcare professionals. Veeva's president, Kilian Weiss, emphasized that 89% of AI initiatives fail due to data challenges, and Servier's data-first approach demonstrates industry leadership. The adoption replaces fragmented silos and ensures consistency for scaling advanced analytics and AI.
- Servier standardizes customer reference data with Veeva OpenData across more than 80 countries.
- The initiative builds on Servier's use of Veeva Link Key People.
Stop Anthropomorphizing LLMs, Treat Them as Tools
AI · Recorded impact score: 1/5
This article argues that marketers and tech professionals fundamentally misunderstand large language models (LLMs) by treating them as conscious entities. It explains that LLMs are statistical pattern engines that predict the next token based on probability, not logical reasoning. This leads to common failures like miscounting letters or clinging to incorrect answers. The author advises abandoning implicit logic by breaking tasks into single steps, providing tight constraints to reduce hallucinations, and not arguing with erroneous outputs. By reframing LLMs as tools rather than coworkers, marketing workflows can be made more effective and efficient.
- LLMs are predictive text engines based on statistical probability, not human logic.
- LLMs break text into tokens, which can obscure letter-level details and cause miscounting.
Explore company relationships
Questions about Veeva
What is Veeva?
Veeva is a public enterprise software company providing cloud applications and data products for life sciences organisations.
Who uses Veeva?
Its users are mainly pharmaceutical, biotech, CRO, regulatory, quality, safety, medical, clinical, and commercial teams inside large life sciences organisations.
How does Veeva make money?
Veeva earns revenue mainly from recurring SaaS subscriptions, plus data subscriptions, modular licensing, and some usage-based fees for newer capabilities.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
5 publicly documented primary sources and citations linked across the market graph.
Start with a company or market. Track what changes.
Create your Polaris7 workspace to explore extended company profiles, organize relevant players into Watchlists, and receive focused briefings when material changes occur.
Veeva
Open extended company details, ownership links, and automated signal monitoring in Polaris7.
